docetaxel + pembrolizumab + vibostolimab

This drug is a combination therapy consisting of three agents: - **Docetaxel** is a chemotherapy agent that inhibits microtubule depolymerization, disrupting cell division and inducing apoptosis in cancer cells. - **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 ligands to restore anti-tumor immune responses. - **Vibostolimab** is a humanized monoclonal antibody targeting TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains), an immune checkpoint receptor. By blocking TIGIT, vibostolimab enhances T-cell activation and antitumor immunity. The combination aims to improve outcomes in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after prior platinum-doublet chemotherapy and PD-(L)1 inhibitor treatment. The coformulation of pembrolizumab and vibostolimab (known as MK-7684A) combined with docetaxel has been evaluated in the Phase 2 KEYVIBE-002 trial. Although it showed an increase in median progression-free survival compared to docetaxel alone, this improvement did not reach statistical significance. Safety profiles were consistent with known effects of each agent[1][3][4][7].

Other names

MK-7684A coformulation plus docetaxelMK7684A coformulation plus docetaxelMK 7684A coformulation plus docetaxel